Warfarin News and Research

RSS

Warfarin is a drug that prevents blood from clotting. It belongs to the family of drugs called anticoagulants (blood thinners).

New article highlights need for optimization of warfarin therapy

Warfarin can be a challenging drug to manage. Long-term anticoagulation is recommended for patients with atrial fibrillation at risk of stroke, and for those with recurrent venous thrombosis or prosthetic heart valves.

1 Apr 2015

Boston Scientific announces successful implantations of WATCHMAN Device in three US patients

This week, three patients in the United States received the first implants of the Boston Scientific Corporation WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device.

25 Mar 2015

UM experts warn of serious risks associated with common IV devices

Every day, patients around the country get IV devices placed in their arms, to make it easier to receive medicines or have blood drawn over the course of days or weeks. But these PICC lines, as they're called, also raise the risk of potentially dangerous blood clots.

23 Mar 2015

UF pharmacy dean to be honored with 2015 SURA Distinguished Scientist Award

SURA today announced that Julie A. Johnson, Dean and Distinguished Professor at the University of Florida's College of Pharmacy, will receive its 2015 SURA Distinguished Scientist Award.

20 Mar 2015

New blood thinner reduces stroke risk in patients with atrial fibrillation

Patients with high-risk atrial fibrillation, or AFib, often require one drug to regulate heart rhythm and a second drug to thin their blood and reduce the risk of stroke.

9 Mar 2015

PCDS AC system optimizes delivery of anticoagulation drugs, reduces adverse events

Point of Care Anticoagulation software (PCDS AC) optimizes delivery of anticoagulation drugs and reduces adverse events associated with anticoagulation therapy. The software was designed and developed in collaboration with leading clinical thrombosis experts, and is a decision support tool that takes the complexity out of AC management by providing a real-time AC dashboard. With intuitive, predictive clinical decision support, PCDS AC transforms evidence-based guidelines into intelligent tools that measure and improve AC therapy outcomes.

25 Feb 2015

Daiichi Sankyo receives FDA approval for SAVAYSA (edoxaban) Tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration has approved SAVAYSA (edoxaban) Tablets, an oral, once-daily selective factor Xa-inhibitor, to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF).

8 Jan 2015

Universal Biosensors announces release of Siemens Xprecia Stride Coagulation Analyzer

Universal Biosensors, Inc. is pleased to announce that Siemens Healthcare Diagnostics Inc. has initiated the European limited release of the Xprecia Stride Coagulation Analyzer, its first point-of-care coagulation testing product.

17 Dec 2014

Studies presented at ASH meeting compare new, standard-of-care treatments for blood clots

Studies presented at the 56th American Society of Hematology Annual Meeting and Exposition compare new and standard-of-care treatments for blood clots and further illuminate clot risks in vulnerable populations, such as cancer patients.

8 Dec 2014

Daiichi Sankyo releases new formulation of LIXIANA 60 mg Tablets

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA 60 mg Tablets (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban, approval to market: September 26, 2014; NHI drug price listing: November 25, 2014) in Japan for the recently approved indications: the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) and the treatment and recurrence prevention of venous thromboembolism (VTE) [deep vein thrombosis (DVT) and pulmonary thromboembolism (PE)].

8 Dec 2014

Three Johns Hopkins hospitals recognized as Top Performer on Key Quality Measures

Three Johns Hopkins Medicine hospitals are recipients of The Joint Commission’s 2013 Top Performer on Key Quality Measures award. The Top Performer program recognizes hospitals for improving performance on evidence-based interventions that increase the chances of healthy outcomes for patients with certain conditions, including heart attack, heart failure, pneumonia, surgical care, children’s asthma, stroke, venous thromboembolism (VTE) and perinatal care, as well as for inpatient psychiatric services and immunizations.

17 Nov 2014

FDA recommens approval of Daiichi Sankyo's once-daily SAVAYSA for patients with NVAF

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 to recommend approval of once-daily SAVAYSA (edoxaban) 60 mg dosing regimen for the reduction in risk of stroke and systemic embolic events (SEE) in patients with non-valvular atrial fibrillation (NVAF).

30 Oct 2014

Blood test can help identify people at increased risk of atrial fibrillation, stroke

Many of those who are genetically predisposed to develop atrial fibrillation, which dramatically raises the risk of stroke, can be identified with a blood test. This is shown by new research from Lund University in Sweden.

3 Oct 2014

New evidence-based guidelines for prevention, treatment of POAF

The American Association for Thoracic Surgery has released new evidence-based guidelines for the prevention and treatment of perioperative and postoperative atrial fibrillation (POAF) and flutter for thoracic surgical procedures.

23 Sep 2014

Digoxin drug increases risk of adverse cardiovascular events or sudden death

Digoxin may increase the risk of death in patients with atrial fibrillation (AF) by approximately 20%, according to results from the ROCKET AF trial presented at ESC Congress today by Dr Manesh Patel, director of interventional cardiology and catheterisation labs at Duke University Health System in Durham, North Carolina, US.

2 Sep 2014

Morbidity, mortality of AF patients remains high at 1 year even with good use of oral anticoagulants

Mortality and morbidity of atrial fibrillation (AF) patients remains high at one year despite good use of oral anticoagulants, according to the one year follow up of the Atrial Fibrillation General Pilot Registry.

1 Sep 2014

Janssen, Bayer announce expansion of EXPLORER global cardiovascular research program for XARELTO

Janssen Research & Development, LLC and its development partner, Bayer HealthCare, announced today the expansion of the EXPLORER global cardiovascular research program for XARELTO (rivaroxaban) to include additional high-risk patient populations.

29 Aug 2014

Armetheon raises $7 million in first round of financing

Armetheon, Inc., a biopharmaceutical company focused on developing novel mid- to late-stage cardiovascular drug candidates, today announced that it has raised $7.0 million in its first round of financing.

28 Aug 2014

Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Mylan Inc. today announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's Xeloda Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated as monotherapy, adjuvant therapy and combination therapy for certain types of breast, colon and colorectal cancers.

11 Aug 2014

New joint ESC/ESA Guidelines on non-cardiac surgery

The publication of the new joint ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management introduces a number of recommendations in the field. Among other topics, the Guidelines include updated information on the use of clinical indices and biomarkers in risk assessment, and the use of novel anticoagulants, statins, aspirin and beta-blockers in risk mitigation.

1 Aug 2014